جست‌وجوی استاد و پژوهشگر

Pratip K. Bhattacharyaمشاهده پروفایل

دانشیار

• Magnetic Resonance Imaging (MRI)
• Hyperpolarized MRI
• Metabolic Imaging
• +۹ مورد دیگر

Pratip K. Bhattacharya, Ph.D. , is an Associate Professor in the Department of Cancer Systems Imaging and the Department of Imaging Physics at The University of Texas MD Anderson Cancer Center, with a joint appointment in the Graduate School of Biomedical Sciences at The University of Texas Health Science Center. He is a principal investigator leading the Bhattacharya Laboratory, dedicated to advancing magnetic resonance imaging (MRI) through hyperpolarization techniques for applications in cancer and cardiovascular diseases. His research focuses on developing real-time metabolic and molecular imaging methods using hyperpolarized 13 C and 15 N-labeled compounds and silicon nanoparticles. These innovative probes significantly enhance MRI sensitivity, enabling non-invasive assessment of tissue metabolism and targeted imaging. His lab's work spans three primary areas: real-time metabolic MR imaging, targeted molecular MR imaging with functionalized silicon nanoparticles, and high-resolution MR metabolomics. These efforts are aimed at improving disease diagnosis and therapy monitoring. Analysis of his recent publications reveals a strong and consistent focus on hyperpolarized MRI, particularly using silicon particles and metabolic tracers like succinate, to visualize cancer metabolism and cardiovascular conditions in vivo. His research integrates physics, chemistry, and biomedical engineering to create novel imaging tools with direct clinical translational potential. PHIP Hyperpolarization Dynamic Nuclear Polarization (DNP) Hyperpolarized Silicon Nanoparticles Real-Time Metabolic Imaging Cancer and Cardiovascular Imaging Theranostic Applications Dr. Bhattacharya actively mentors graduate students and postdoctoral fellows, including Saleh Ramezani, Jose Enriquez, Dontrey Bourgeois, and Kang-Lin Hsieh. He collaborates closely with physician-scientists, radiologists, and oncologists to ensure his imaging science innovations address critical clinical needs. His laboratory is supported by grant funding, facilitating the development of cutting-edge imaging technologies. The Bhattacharya Laboratory is a key component of the Division of Diagnostic Imaging at MD Anderson, fostering a collaborative environment for interdisciplinary research. The lab focuses on translating fundamental discoveries in hyperpolarization physics into practical tools for improving cancer care.

• Radiation Oncology
• Medical Physics
• Computational Radiation Oncology
• +۶ مورد دیگر

Ivaylo Mihaylov is Professor of Clinical Radiation Oncology at the University of Miami Miller School of Medicine with dual appointment as Adjunct Associate Professor in Biomedical Engineering. Previously held faculty positions at University of Arkansas for Medical Sciences, Brown University, and University of Rhode Island. His educational background includes: PhD in Theoretical Astrophysics, University of Toledo (2003) MS, Sofia University, Bulgaria (1996) Post-Doctoral Fellowship in Radiation Oncology, Virginia Commonwealth University (2006) Research spans computational radiation oncology including radiation transport theory, Monte Carlo modeling, and image processing. Pioneered incorporation of CT-based tissue density into radiotherapy optimization. Current focus on radiation-immunotherapy synergy targeting metastatic cancer via abscopal effect mechanisms. Recent publications (2021-2023) analyze immunotherapy-radiation interactions, emphasizing pneumonitis prediction through radiomics and biomarker identification in lung cancer/glioblastoma. Work bridges computational modeling with clinical translation in cancer treatment. Mentors PhD candidates in CAMPEP-accredited Medical Physics program and teaches residents in dosimetry, optimization algorithms, and Journal Club since 2013. Board-certified Therapeutic Medical Physicist (ABR) with Florida licensure. Active in Radiation Oncology department and Biomedical Engineering program, integrating clinical service with academic innovation in treatment planning and cancer immunology.

• Head and Neck Cancer
• Radiation Oncology
• HPV-associated Oropharyngeal Cancer
• +۷ مورد دیگر

Dr. Jason Chan is an Associate Professor in the Department of Radiation Oncology at the University of California, San Francisco (UCSF) School of Medicine. His clinical practice focuses on the treatment of head and neck, skull base, cutaneous, and thoracic malignancies, offering advanced techniques including Cyberknife radiosurgery and high-dose-rate brachytherapy for both initial and repeat radiotherapy. Dr. Chan received his medical degree from Brown University and completed his Internal Medicine internship at Kaiser Permanente San Francisco followed by a residency in Radiation Oncology at UCSF. His academic journey has positioned him as a prominent researcher in head and neck oncology, with particular expertise in HPV-associated oropharyngeal cancer, nasopharyngeal cancer, lung cancer, thyroid cancer, and cutaneous malignancies. His research spans multiple domains including radiation therapy optimization, AI applications in radiation oncology, cancer outcomes research, and translational studies. Dr. Chan's work frequently addresses critical questions in treatment de-escalation for HPV-positive cancers, reirradiation techniques, and health disparities in cancer outcomes. Recent publications demonstrate his leadership in investigating swallowing function outcomes, dosimetric analysis of brachytherapy, and the impact of socioeconomic factors on nasopharyngeal carcinoma outcomes. Dr. Chan actively participates in numerous clinical trials and translational studies, particularly in head and neck and lung cancers. His collaborative approach is evident in his extensive co-authorship network with colleagues at UCSF and other institutions. His work bridges clinical practice with technological innovation, especially in the application of artificial intelligence to radiation therapy planning and delivery. Dr. Chan's research portfolio reflects a commitment to improving both the precision and accessibility of cancer care while addressing significant clinical challenges in radiation oncology.

Alexander Kabanovمشاهده پروفایل

استاد

• Drug Delivery
• Nanomedicine
• Polymer Chemistry
• +۳ مورد دیگر

Dr. Alexander Kabanov is the Mescal S. Ferguson Distinguished Professor at the University of North Carolina School of Pharmacy and a member of the UNC Lineberger Comprehensive Cancer Center. He directs the Center for Nanotechnology in Drug Delivery and co-directs the Carolina Institute for Nanomedicine at UNC-Chapel Hill. Previously, he was a Parke-Davis Professor and Director of the Center for Drug Delivery and Nanomedicine at the University of Nebraska Medical Center (1994–2012). Education : PhD in Chemical Kinetics and Catalysis (1987, Moscow State University), DSc in USSR. Research Interests focus on nanomedicine and drug delivery systems , including: Polymeric micelles for cancer therapy Polyion complexes for CNS delivery Nanogels for protein/peptide delivery Magnetic nanoparticle actuation PEGylation alternatives Exosome-based therapeutics His scientific impact includes over 240 peer-reviewed articles (H-index 73), 100 patents, and $110M+ in cumulative research funding. Key article themes span nanocarrier design, tumor microenvironment targeting, and clinical translation of polymeric micelle technology. Notable awards include: AAAS Fellow (2021) NSF Career Award (1995) UNMC Scientist Laureate (2009) Lenin Komsomol Prize (1988) Dr. Kabanov co-founded Supratek Pharma and established the Nanomedicine and Drug Delivery Symposium series . His work led to SP1049C , a first-in-man polymeric micelle drug for cancer now in Phase II clinical trials.

• Experimental Cancer Medicine
• Ovarian Cancer
• Colorectal Cancer
• +۳ مورد دیگر

Patricia Roxburgh is a Professor of Experimental Cancer Medicine at the University of Glasgow, affiliated with the Clinical Research Garscube. Her research focuses on gynaecological cancers, particularly ovarian and colorectal malignancies, with an emphasis on genomic alterations, targeted therapies, and clinical trial design. Education: Not explicitly stated Appointments: University of Glasgow, Beatson Cancer Charity, Cancer Research UK Roxburgh's work spans BRCA mutations, PARP inhibitors, and the role of biomarkers like p53 and CA-125 in treatment response. She explores epigenetic mechanisms, immune modulation, and precision medicine strategies. The 15 most recent articles highlight her contributions to ovarian cancer genomics (e.g., structural variants, multiomic patient stratification), drug combination studies (PARP inhibitors with immunotherapies, capecitabine with radiotherapy), and biomarker validation (CA-125 as a prognostic indicator, p53 mutation dynamics). Grants: Genomic landscape of ovarian cancer (Tenovus Scotland), IMAGINE (Beatson Cancer Charity), PAIRS (Wellbeing of Women), Precision Medicine Laboratory sequencing (Beatson Cancer Charity) Current Projects: ECMC QQR, CRUK Centre Renewal, NHS ovarian cancer studies Roxburgh collaborates with teams at the Institute of Cancer Sciences and participates in clinical trials targeting chemoresistance, immunotherapy, and personalized treatment regimens.

• Genome Stability
• DNA Repair Mechanisms
• Cancer Biology
• +۳ مورد دیگر

J. Ross Chapman is a Professor of Genome Maintenance Biology at the University of Oxford, affiliated with the MRC Molecular Haematology Unit. He holds fellowships from Cancer Research UK and the Lister Institute, and is part of the EMBO Young Investigator Programme. His research focuses on DNA repair mechanisms, particularly the balance between accurate and mutagenic repair pathways in cancer and immune disorders. Career highlights include roles as a Sir Henry Wellcome Fellow and Principal Investigator. His group studies genetic recombination mechanisms, aiming to develop cancer therapies targeting repair pathway dysfunctions. Key research areas include the role of BRCA1, BARD1, 53BP1, and CST complexes in DNA repair. Awards include CRUK and Lister Institute Fellowships, alongside EMBO recognition. His lab’s work spans genomic stability, immune system development, and cancer therapy strategies. Recent studies explore chronic inflammation in leukemia evolution and synthetic lethality in BRCA-deficient cells.

Julie K. Schwarzمشاهده پروفایل

استاد

• Cervical Cancer
• Gynecologic Oncology
• Radiation Oncology
• +۹ مورد دیگر

Julie K. Schwarz, MD, PhD, FASTRO is a tenured Professor of Radiation Oncology at Washington University School of Medicine, where she serves as Vice-Chair of Research and Director of the Cancer Biology Division. She also holds appointments as Professor of Cell Biology and Physiology and is affiliated with the Roy and Diana Vagelos Division of Biology & Biomedical Sciences, specifically within the Cancer Biology and Molecular Cell Biology programs. Dr. Schwarz is a key member of the Siteman Cancer Center and co-leads one of only five centers comprising the NIH's Radiation Oncology-Biology Integration Network (ROBIN). Dr. Schwarz completed her BS in Biology at Duke University (1995) followed by an MD/PhD in Cell and Molecular Biology at Washington University School of Medicine (2004) through the Medical Scientist Training Program. She completed her Internal Medicine internship (2005) and Radiation Oncology residency (2009) at Barnes-Jewish Hospital, becoming board-certified by the American Board of Radiology in Radiation Oncology (2010). Her research program focuses on translational studies of gynecologic cancers, particularly cervical cancer, with emphasis on tumor metabolism, biomarker discovery, and treatment resistance mechanisms. Dr. Schwarz's laboratory maintains one of the largest tumor repositories for cervical cancer, which includes specimens collected before and during chemoradiation treatment. Her work has demonstrated the critical role of pretreatment and post-treatment FDG-PET scanning for cervical cancer patients and has identified alterations in PI3K/Akt pathway genes associated with treatment response. Recent research directions include studying obesity's paradoxical favorable impact on cervical cancer outcomes, glucose and glutamine metabolism as targets for cancer therapy, and the role of tumor immunology in therapy resistance. Analysis of Dr. Schwarz's most recent publications reveals a strong focus on cervical cancer biology, tumor metabolism, and novel therapeutic approaches. Her work integrates clinical data with laboratory research to identify biomarkers and develop improved treatment strategies. Current research emphasizes the interface between tumor metabolism, the microenvironment, and response to therapy, with particular attention to HPV-related cancers, tumor imaging, and metabolic targets for radiosensitization. Fellow of American Society for Radiation Oncology (ASTRO) (2024) Danforth WashU Physician-Scientist Scholar Award (2024) Elected into American Society for Clinical Investigation (2022) Michael Fry Research Award for Outstanding Junior Investigator: Radiation Research Society (2012) Fellow: National Cancer Care Network (2008) RSNA Roentgen Resident/Fellow Research Award (2008) As a dedicated mentor, Dr. Schwarz has guided numerous trainees across all levels including undergraduates, graduate students, medical students, residents, fellows, and postdoctoral researchers. Her Schwarz Lab is highly collaborative and actively recruits students and researchers, with recent successes including Leahan Castillo receiving an Honorable Mention at AACR and Brett Tortelli developing significant research on the vaginal microbiome's relationship to cervical cancer treatment response. Dr. Schwarz is R01-funded and leads multiple research projects, including work on the TARGET Center which focuses on understanding the biologic effects of radiation therapy in cancer treatment. She actively participates in national organizations including the ASTRO/NCI Radiobiology Consensus Workshop, AACR Radiation Oncology Think Tank, and the ASTRO Community of Radiation Oncology Physician Scientists. Dr. Schwarz directs the Schwarz Lab, which is growing and actively recruiting postdocs, staff scientists, and graduate students. The lab employs a multidisciplinary approach combining well-annotated clinical databases, prospectively collected patient tumor banks, and state-of-the-art sequencing technologies. Current research directions include single-cell sequencing approaches to study treatment effects on tumor cells and immune cells within the tumor microenvironment, glucose and glutamine metabolism as targets for cancer therapy, and targeting myeloid-derived cells to improve anti-tumor immunity. The lab is highly collaborative and studies multiple tumor types including cervical, pancreatic, and ovarian cancers.

• Neuroblastoma
• Pediatric Oncology
• Translational Research
• +۳ مورد دیگر

Dr. Katherine Matthay is a **Professor in the Department of Pediatrics at the UCSF School of Medicine** and the **Leader of the Pediatric Malignancies Program** in the Helen Diller Family Comprehensive Cancer Center. Her work focuses on **translational research in neuroblastoma**, with a particular emphasis on improving therapies and global oncology initiatives. She has led the **Global Neuroblastoma Network**, an international tumor board for resource-limited countries, and contributed to clinical trials and protocols for neuroblastoma treatment. **Research Interests**: Dr. Matthay’s research spans neuroblastoma biology, therapeutic strategies, and global health. She explores mechanisms driving tumor progression, drug resistance, and the development of targeted therapies. Her global efforts include mentoring projects in Africa and Central America, and adapting treatments for low-resource settings. **Articles**: Her recent work includes studies on Aurora Kinase A inhibition, ALK-driven therapies, and predictive biomarkers for MIBG response. These articles highlight advancements in drug combinations, molecular pathways, and global collaboration. **Awards**: While no specific awards are listed here, her contributions to neuroblastoma research and global health are widely recognized in the field. **Advising & Grants**: She leads large-scale clinical trials and collaborates with international teams. Her work includes optimizing response criteria and post-treatment follow-up in neuroblastoma. **Labs/Teams**: Active in the Helen Diller Cancer Center and the Global Neuroblastoma Network, fostering multidisciplinary approaches to pediatric oncology.

• Radiation Oncology
• Cancer Biology
• Molecular Targeted Therapy
• +۷ مورد دیگر

Joseph N. Contessa, MD, PhD is an Adjunct Professor of Therapeutic Radiology and Pharmacology at Yale School of Medicine, where he serves as Director of Yale Medicine's Central Nervous System Radiotherapy Program. His clinical practice focuses on treating patients with brain tumors, head and neck cancers, and tumors at the base of the skull, including rare entities such as low-grade and malignant gliomas, ependymomas, high-grade meningiomas, hemangiopericytomas, paragangliomas, and schwannomas. Dr. Contessa's research spans multiple areas of cancer biology with a particular emphasis on molecular mechanisms of therapeutic resistance and novel approaches to radiosensitization. His work explores the role of N-linked glycosylation in cancer progression and treatment resistance, developing small molecule inhibitors targeting this pathway to overcome resistance to EGFR tyrosine kinase inhibitors. He also investigates targeted therapies for head and neck squamous cell carcinoma, molecular imaging of the epidermal growth factor receptor, and drug discovery through high-throughput screening approaches. Analysis of Dr. Contessa's recent publications reveals a consistent focus on the intersection of radiation oncology and molecular biology, particularly examining how glycosylation pathways influence cancer cell response to radiation and targeted therapies. His work spans basic science investigations into protein folding and quality control mechanisms to clinical applications in lung cancer, brain tumors, and head and neck cancers. A significant portion of his research explores how inhibiting specific glycosylation enzymes can sensitize tumors to radiation therapy. Dr. Contessa actively collaborates with leading researchers at Yale including Veronica Chiang (6 publications), Barbara Burtness (2 publications), Kimberly Johung (2 publications), and Scott Gettinger (2 publications). He serves as a Sub Investigator on the clinical trial 'Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer' (HIC ID 1603017333), which is scheduled for primary completion in June 2026. His laboratory work is closely integrated with clinical care through multiple Yale centers including the Brain Tumor Center, Gamma Knife Center, Head and Neck Cancers Program, and Yale Cancer Center. Dr. Contessa's research bridges basic science discoveries in protein glycosylation with clinical applications in radiation oncology, creating a translational pipeline from bench to bedside for patients with challenging malignancies.

Andrew Z. Wangمشاهده پروفایل

استاد

• Cancer Research
• Nanotechnology
• Biomedical Engineering
• +۲ مورد دیگر

Andrew Z. Wang, M.D., is a tenured Professor and holds the A. Kenneth Pye Professorship in Cancer Research at the University of Texas Southwestern. He serves as Vice Chair for Translational Research and Commercialization in the Department of Radiation Oncology, having joined UTSW in August 2021. Previously, he held faculty positions at the University of North Carolina, where he rose from Assistant to Tenured Professor. Dr. Wang's research integrates biomedical engineering with oncology to develop innovative cancer diagnostics and therapeutics. His work focuses on: Nanotechnology-enabled drug delivery systems Cancer immunotherapy and vaccine development Biomaterial applications in oncology Liquid biopsy technologies for treatment monitoring Radiotherapy-enhancing strategies His 128+ publications demonstrate consistent focus on translational nanomedicine, with recent works advancing combination therapies (chemoradiation-immunotherapy), 3D-printed medical devices, and machine learning applications in oncology. Clinical publications emphasize optimizing radiation techniques for genitourinary/gastrointestinal cancers. Major scientific recognitions include: Fellow of the American Association for the Advancement of Science (AAAS) Fellow of the American Institute for Medical and Biological Engineering (AIMBE) Fellow of the American Society for Clinical Investigation (ASCI) A. Kenneth Pye Professorship in Cancer Research Dr. Wang leads a prolific research program generating 38 patents and founding three biotechnology startups. Clinically, he specializes in advanced radiation techniques (IMRT, SBRT, brachytherapy) for genitourinary and gastrointestinal malignancies.

Shreya Goelمشاهده پروفایل

استادیار

• Molecular Imaging
• Biologics Engineering
• Radionuclide Therapy
• +۷ مورد دیگر

Shreya Goel is an Assistant Professor at the University of Utah , affiliated with the College of Pharmacy (Molecular Pharmaceutics) and the School of Medicine (Radiology and Imaging Sciences). Her research focuses on integrating molecular imaging , biologics engineering , and theranostics to develop innovative cancer therapies. PhD: University of Wisconsin-Madison Her work leverages positron emission tomography (PET) , optoacoustic imaging , and nanotechnology to visualize disease microenvironments, optimize radionuclide therapies , and enhance pharmacokinetic/pharmacodynamic modeling for drug development. Current projects include mitochondrial metabolism targeting in pediatric tumors, ultrasmall nanoprobes for surgical guidance, and hypoxia alleviation strategies in cancer treatment. Publications highlight advancements in imaging-guided radiotherapy , nanoprobe design , and multispectral optoacoustic tomography for tumor microenvironment analysis. Her lab actively recruits graduate students and postdoctoral researchers for interdisciplinary projects in pediatric oncology , radiopharmaceuticals , and biologics .

Susann M. Brady-Kalnayمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Imaging
• Receptor Protein Tyrosine Phosphatases (RPTPs)
• +۹ مورد دیگر

Susann M. Brady-Kalnay, PhD , is the Sally S. Morley Designated Professor of Brain Tumor Research at the Case Western Reserve University (CWRU) School of Medicine. She holds professorships in the Departments of Molecular Biology and Microbiology, Neurosciences, and Pathology, and is a member of the Cancer Imaging Program at the Case Comprehensive Cancer Center. Her work bridges molecular biology, cancer imaging, and targeted therapy. Research Interests : Dr. Brady-Kalnay specializes in receptor protein tyrosine phosphatases (PTPs) in cancer progression cell adhesion dynamics in brain tumors signal transduction mechanisms molecular imaging agents for tumor detection novel therapeutics targeting proteolyzed PTPmu fragments Her lab's landmark discovery of PTPmu proteolysis in glioblastoma multiforme (GBM) has led to platform technologies for "see(k) and destroy" cancer strategies. Imaging Innovations : The lab develops fluorescent peptides (e.g., SBK2) for real-time surgical imaging SBK2-Gd MRI agents with superior tumor contrast radioisotope-conjugated PET agents for targeted radiotherapy nanoparticle diagnostics for invasive gliomas ultrasound nanobubble contrast agents These tools address critical gaps in imaging tumor boundaries and microenvironment interactions. Scientific Awards : Elected Senior Member, National Academy of Inventors (2022) Equalize National Woman Academic Inventor Finalist (2021) Mather Spotlight Prize for Women of Achievement, CWRU (2019) Distinguished Faculty Researcher, CWRU (2018) Special Achievement Award, University of Dayton National Alumni Association (2011)

S. Marshal Isaacsمشاهده پروفایل

استاد

• Emergency Medicine
• Prehospital Care
• Clinical Trials
• +۵ مورد دیگر

Dr. S. Marshal Isaacs is a distinguished Professor of Emergency Medicine at the University of Texas Southwestern Medical School and a senior faculty member at Parkland Hospital's Emergency-Trauma Center. As Medical Director of the Dallas Fire-Rescue Department (DFR), he oversees one of the nation's busiest EMS systems (500 daily incidents, 400+ paramedics). His career includes 12 years as Medical Director for the San Francisco Fire Department, renowned for advancing prehospital care, AED programs, and clinical trials. He collaborates closely with EMS leaders like Drs. Ray Fowler and Kathy Rinnert to enhance Dallas' BioTel System, a 15-municipality EMS federation. Dr. Isaacs' academic roles include NIH-funded research through the ROC consortium and teaching EM residents. His clinical expertise spans otology/neurotology, surgical innovation (e.g., endoscopic ear surgery), and radiation oncology for skull base tumors. He co-authored key NAEMSP texts and pioneered bacteriophage therapy for mastoiditis. Awards include the prestigious Michael K. Copass Award for EMS excellence. Education: Union College, SUNY Stony Brook Medical School (1988), residency at Allegheny General Hospital (Pittsburgh), and a Stanford University EMS fellowship. He served as SFGH's Chief Flight Physician and UCSF faculty before joining UTSW. Current initiatives include the Dallas EMS Vision Process and interdisciplinary NIH projects.

• Exercise Oncology
• Cancer Rehabilitation
• Prostate Cancer Treatment
• +۳ مورد دیگر

Professor Daniel Galvão is a leading academic in exercise oncology at Edith Cowan University (ECU), Australia. He serves as Director of the Exercise Medicine Research Institute and holds a Professorship in Exercise and Sports Science within the School of Medical and Health Sciences. His research focuses on optimizing exercise interventions to mitigate treatment-related toxicities and improve outcomes for cancer patients, particularly those with prostate cancer. Galvão has secured over $26 million in grants from bodies like the NHMRC, Movember Foundation, and Cancer Australia, supporting multidisciplinary trials and survivorship programs. Education: PhD (Edith Cowan University, 2006), Master of Applied Science in Clinical Exercise Science (University of Queensland, 2003). His career includes roles as Co-Director of ECU’s Health and Wellness Institute and Fellowships with the American College of Sports Medicine and Exercise and Sports Science Australia. Research emphasizes exercise as medicine in oncology, with over 200 peer-reviewed publications. Key contributions include guidelines for exercise in cancer patients and landmark trials like ERADICATE (prostate cancer radiotherapy adjuncts) and TelEX (weight management for prostate cancer). Notable awards include the 2021 Asian Pacific Prostate Cancer Conference Best Poster, 2014 Edith Cowan Vice-Chancellor’s Award, and 2007 ESSA PhD Medal. He chairs national research committees and reviews for high-impact journals like Journal of Clinical Oncology and European Urology . Current initiatives include nationwide exercise programs for prostate cancer survivors and translational research on myokine mechanisms in cancer suppression. His work bridges clinical practice with evidence-based interventions to enhance patient quality of life and survival outcomes.

• Molecular Imaging
• Radiopharmaceuticals
• Cancer Targeting
• +۷ مورد دیگر

Mary Rusckowski, PhD, is an Associate Professor in the Department of Radiology at UMass Chan Medical School and holds an additional appointment at the T.H. Chan School of Medicine. Her research focuses on developing novel radiopharmaceuticals and molecular imaging agents for cancer, infection, and other diseases. Education: BA in Biology, Albertus Magnus College PhD in Biochemistry, Rutgers University Research Interests: Rusckowski's work integrates chemistry, biology, and imaging to create targeted diagnostic and therapeutic agents. Her major areas include: Design of radiolabeled antisense oligonucleotides for infection and cancer imaging Pretargeting strategies using morpholino oligomers and complementary chemistry Nanoparticle-based delivery systems for theranostics Development of novel chelators and radiolabeling techniques for technetium, indium, and lutetium isotopes Publication Trends: Her extensive publication record (1997–2024) reveals a consistent focus on advancing nuclear medicine and molecular imaging. Recent works emphasize infection-specific imaging agents, VEGF-targeted radiotherapy, and precision delivery systems for dermatological and neurological applications. Labs and Collaborations: While specific lab names are not provided, her co-authorship network includes prominent researchers such as Dale Greiner, John Harris, and Robert Brown, indicating active collaboration within UMass Chan and beyond.